overall survival one year [clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791]

overall survival one year [clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791]

erlotinib followed at progression by gemcitabine and cisplatin
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791
clinicaltrials:NCT00349219
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

overall survival one year [clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791]

erlotinib followed at progression by gemcitabine and cisplatin
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791
Bio2RDF identifier
76a04cada5bc029084c8f30da7a95791
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
description
erlotinib followed at progression by gemcitabine and cisplatin
identifier
clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791
title
overall survival one year
@en
inDataset
type
label
overall survival one year [clinicaltrials_resource:76a04cada5bc029084c8f30da7a95791]
@en